JP2006507347A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006507347A5 JP2006507347A5 JP2004555591A JP2004555591A JP2006507347A5 JP 2006507347 A5 JP2006507347 A5 JP 2006507347A5 JP 2004555591 A JP2004555591 A JP 2004555591A JP 2004555591 A JP2004555591 A JP 2004555591A JP 2006507347 A5 JP2006507347 A5 JP 2006507347A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- group
- unsubstituted
- compound
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 59
- 125000000217 alkyl group Chemical group 0.000 claims 29
- 125000001072 heteroaryl group Chemical group 0.000 claims 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 17
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 13
- 239000012453 solvate Substances 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 125000001309 chloro group Chemical group Cl* 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 150000002367 halogens Chemical group 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 208000023504 respiratory system disease Diseases 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000002541 furyl group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 230000004957 immunoregulator effect Effects 0.000 claims 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000000884 Airway Obstruction Diseases 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063897 Renal ischaemia Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000036284 Rhinitis seasonal Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- -1 —NR 4 R 5 Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42886102P | 2002-11-25 | 2002-11-25 | |
| PCT/US2003/037366 WO2004048322A1 (en) | 2002-11-25 | 2003-11-21 | Cannabinoid receptor ligands |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009247114A Division JP2010059169A (ja) | 2002-11-25 | 2009-10-27 | カンナビノイドレセプターリガンド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006507347A JP2006507347A (ja) | 2006-03-02 |
| JP2006507347A5 true JP2006507347A5 (OSRAM) | 2006-10-19 |
| JP4455339B2 JP4455339B2 (ja) | 2010-04-21 |
Family
ID=32393468
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004555591A Expired - Fee Related JP4455339B2 (ja) | 2002-11-25 | 2003-11-21 | カンナビノイドレセプターリガンド |
| JP2009247114A Withdrawn JP2010059169A (ja) | 2002-11-25 | 2009-10-27 | カンナビノイドレセプターリガンド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009247114A Withdrawn JP2010059169A (ja) | 2002-11-25 | 2009-10-27 | カンナビノイドレセプターリガンド |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7253189B2 (OSRAM) |
| EP (1) | EP1565431B1 (OSRAM) |
| JP (2) | JP4455339B2 (OSRAM) |
| CN (1) | CN100349862C (OSRAM) |
| AR (1) | AR042120A1 (OSRAM) |
| AT (1) | ATE433956T1 (OSRAM) |
| AU (1) | AU2003294449A1 (OSRAM) |
| CA (1) | CA2506895A1 (OSRAM) |
| DE (1) | DE60328033D1 (OSRAM) |
| ES (1) | ES2327515T3 (OSRAM) |
| MX (1) | MXPA05005512A (OSRAM) |
| TW (1) | TW200413297A (OSRAM) |
| WO (1) | WO2004048322A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100107509A (ko) * | 2001-09-14 | 2010-10-05 | 9222-9129 퀘벡 인코포레이티드 | 히스톤 데아세틸라아제의 억제제 |
| US7868204B2 (en) * | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US6897220B2 (en) * | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| EP1663953A1 (en) * | 2003-09-24 | 2006-06-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US7253204B2 (en) * | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
| CA2585172C (en) * | 2004-10-29 | 2014-08-12 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as modulators of ppar |
| CN101466670B (zh) * | 2006-04-07 | 2013-04-17 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| TW201012803A (en) * | 2008-06-06 | 2010-04-01 | Organon Nv | Heterocyclic derivatives |
| CN103265480B (zh) * | 2013-05-11 | 2015-10-07 | 浙江大学 | 喹啉二酮类衍生物及其制备方法和用途 |
| US9636298B2 (en) | 2014-01-17 | 2017-05-02 | Methylgene Inc. | Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs |
| TWI642658B (zh) | 2017-11-01 | 2018-12-01 | 國立臺灣師範大學 | 茚並異喹啉衍生物的製備方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338753A (en) | 1992-07-14 | 1994-08-16 | Sumner H. Burstein | (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics |
| FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| IT1271266B (it) | 1994-12-14 | 1997-05-27 | Valle Francesco Della | Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi |
| US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
| FR2735774B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| FR2742148B1 (fr) | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| AU1618697A (en) | 1996-02-06 | 1997-08-28 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
| NZ333322A (en) * | 1996-07-01 | 2000-06-23 | Schering Corp | Di-N-substituted piperazines and 1,4-di-substituted piperidines as muscarinic antagonists |
| EP0979228A4 (en) | 1997-03-18 | 2000-05-03 | Smithkline Beecham Corp | CANNABINOID RECEPTOR AGONISTS |
| US7507767B2 (en) | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
| US7067539B2 (en) | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
| HUP0401924A3 (en) | 2001-11-14 | 2009-07-28 | Schering Corp | Cannabinoid receptor ligands, their use and pharmaceutical compositions containing them |
-
2003
- 2003-11-21 TW TW092132736A patent/TW200413297A/zh unknown
- 2003-11-21 CA CA002506895A patent/CA2506895A1/en not_active Abandoned
- 2003-11-21 AR ARP030104314A patent/AR042120A1/es unknown
- 2003-11-21 AT AT03789933T patent/ATE433956T1/de not_active IP Right Cessation
- 2003-11-21 JP JP2004555591A patent/JP4455339B2/ja not_active Expired - Fee Related
- 2003-11-21 EP EP03789933A patent/EP1565431B1/en not_active Expired - Lifetime
- 2003-11-21 CN CNB2003801090912A patent/CN100349862C/zh not_active Expired - Fee Related
- 2003-11-21 US US10/721,015 patent/US7253189B2/en not_active Expired - Fee Related
- 2003-11-21 DE DE60328033T patent/DE60328033D1/de not_active Expired - Lifetime
- 2003-11-21 ES ES03789933T patent/ES2327515T3/es not_active Expired - Lifetime
- 2003-11-21 AU AU2003294449A patent/AU2003294449A1/en not_active Abandoned
- 2003-11-21 WO PCT/US2003/037366 patent/WO2004048322A1/en not_active Ceased
- 2003-11-21 MX MXPA05005512A patent/MXPA05005512A/es active IP Right Grant
-
2009
- 2009-10-27 JP JP2009247114A patent/JP2010059169A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008503585A5 (OSRAM) | ||
| JP6193922B2 (ja) | ハロアルキルヘテロアリールベンズアミド化合物 | |
| JP5676258B2 (ja) | アルキルスルホニル置換チアゾリド化合物 | |
| JP2019031560A5 (OSRAM) | ||
| JP5855162B2 (ja) | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 | |
| CN1950371B (zh) | 用作组胺h3受体配体的四氢萘啶衍生物 | |
| JP2006507347A5 (OSRAM) | ||
| JP2010540593A5 (OSRAM) | ||
| US20080146576A1 (en) | N-(1-Phthalazin-1-ylpiperidin-4-yl)amides as EP2 receptor modulators | |
| CN102112449A (zh) | 苯基或吡啶基取代的吲唑衍生物 | |
| JP2010539110A5 (OSRAM) | ||
| JP2006524222A5 (OSRAM) | ||
| JP2009534407A5 (OSRAM) | ||
| CN101679299A (zh) | 作为代谢型谷氨酸受体-5调节剂的烟酸衍生物 | |
| ZA200403685B (en) | Cannabinoid receptor ligands. | |
| CN106573001A (zh) | 作为蛋白激酶抑制剂的氨基哒嗪酮化合物 | |
| JP2017501234A5 (OSRAM) | ||
| JP2011509991A (ja) | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 | |
| JP2013525458A (ja) | 抗癌及び抗増殖活性を示すシクロプロピルジカルボキサミド及び類似体 | |
| JP2005505618A5 (OSRAM) | ||
| JP2009526037A (ja) | トリアゾロピリジン化合物 | |
| CN103228643B (zh) | 作为组胺h4受体配体的苯并唑衍生物 | |
| WO2006069525A1 (en) | Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof | |
| CA2565852A1 (en) | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands | |
| RS58809B1 (sr) | Derivat 2-acilaminotiazola za upotrebu u prevenciji ili lečenju oboljenja bešike/urinarnog trakta |